Opinion|Videos|January 21, 2025
The Impact of Trastuzumab Deruxtecan on Clinical Practice for HER2+ Advanced BC and Brain Mets
Panelists discuss how the DESTINY-Breast12 trial has influenced their approach to using trastuzumab deruxtecan (T-DXd) for patients with HER2-positive advanced breast cancer with brain metastases, highlighting the patient subgroups most likely to benefit from T-DXd and its impact on treatment sequencing for those with active brain metastases.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How has the DESTINY-Breast12 trial impacted your view on using T-DXd for patients with HER2-positive advanced breast cancer and brain metastases?
- Which patient subgroups are most likely to benefit from T-DXd, and how do these data influence treatment sequencing for those with active brain metastases?
Advertisement
Related to this article
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
Dana-Farber’s Xin Gu, PhD, and Nicholas Polizzi, PhD, received NIH New Innovator Awards for high-risk, high-reward research.
The c-Met–directed ADC-based combination was designated for mCRC previously treated with fluoropyrimidine, irinotecan, oxaliplatin, and anti-VEGF therapy.
Pooled data from 3 randomized trials showed ropeginterferon alfa-2b improved responses vs phlebotomy alone but not vs hydroxyurea in polycythemia vera.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
FDA Grants Breakthrough Therapy Designation to Telisotuzumab Adizutecan Plus Bevacizumab in Refractory mCRC
3
Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC
4
FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC
5